Background {#Sec1}
==========

Autoimmune pancreatitis (AIP) was first proposed as a clinical entity by Yoshida et al. in 1995 \[[@CR1]\]. Current consensus suggests AIP encompasses two different types with distinct histological and clinical profiling. Type 1 AIP is recognized as a pancreatic manifestation of IgG4-related systemic disease. Histologically, it is termed lymphoplasmacytic sclerosing pancreatitis (LPSP) or AIP without granulocyte epithelial lesions (GELs). It is characterized by periductal infiltration of lymphocytes, storiform fibrosis, abundant IgG4-positive plasma cells, and obliterative phlebitis. Clinically, predominance has been observed in elderly males, with elevated serum IgG4 levels, accompanying extrapancreatic involvement (like bile ducts, salivary glands, retroperitoneum, kidneys etc.), and an exclusive response to steroids \[[@CR2]--[@CR5]\]. The prognosis is considered favorable. The long-term survival of type 1 AIP patients has been proved to be comparable to the age- and gender-matched subjects from the general population \[[@CR4]\]. The treatment primarily involves inducing remission and reducing relapse with steroids or sometimes immunosuppressants \[[@CR6], [@CR7]\].

The synchronous and metachronous occurrences of type 1 AIP and pancreatic tumors (PaT) have been previously reported. In AIP patients, the occurrence rate of PaT is about 0.1--4.8% \[[@CR5]--[@CR12]\]. This co-occurrence suggests that the definitive diagnosis of AIP cannot rule out the concurrent presence of PaT. When PaT is identified in AIP patients, management changes to diagnostic and therapeutic workup for cancer, where the principal therapy is surgical resection accompanied by chemotherapy, radiation therapy or targeted medical treatment. The prognosis would be variably poorer than that of pure AIP cases, depending on the subtype, stage and therapy choice of the concurrent PaT \[[@CR13], [@CR14]\]. However, AIP shares similar clinical and radiological manifestations with PaT where diagnosis can be challenging. This includes: abdominal pain, obstructive jaundice, weight loss, elevation of serum IgG4 and CA-199 levels, mass formation in pancreas, pancreatic atrophy, narrowing of main pancreatic duct (MPD) and common bile duct (CBD), decreased enhancement compared to normal pancreas, and peripancreatic vessel stricture \[[@CR5], [@CR15]\]. These features may obscure the diagnosis of concurrent PaT in patients with AIP, which subsequently lead to the delay of appropriate therapy. As far as we know, several studies have attempted to increase the detection of concurrent tumor in AIP, but many non-PaT tumors were also studied \[[@CR8], [@CR12], [@CR16]\]. Only one study has investigated the difference between AIP patients with and without PaT, where no significant difference was observed \[[@CR8]\]. The purpose of this study was to further evaluate the clinical and radiological markers with the aim to increase the detection of concurrent PaT in type 1 AIP.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The study proposal was reviewed by the ethical committee of our institution where the need for informed patient consent was waived. Patient data from two medical institutions between January 2010 and April 2019 were retrospectively reviewed. The inclusion criteria were as follows: 1) completion of dual-phase enhanced abdominal CT imaging before any invasive procedures to the pancreas, 2) a final diagnosis of probable or definitive type 1 AIP in accordance to the international consensus diagnostic criteria proposed in 2011 \[[@CR2]\], 3) at least one month of follow-up with imaging modalities including CT, MRI, fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography/CT (^18^F-FDG PET/CT) or ultrasonography (US) unless AIP and PaT were identified simultaneously. A total of 74 patients (56 from the first institution and 18 from the second institution) diagnosed with type 1 AIP were included (Fig. [1](#Fig1){ref-type="fig"}). The presence of PaT in AIP patients was confirmed histologically, and the absence of PaT in AIP patients was defined as no definite pathological or radiological evidence of PaT until the end of surveillance period. Fig. 1Flow diagram of study population. \* If type 1 autoimmune pancreatitis and pancreatic tumor were identified at the same time, one-month surveillance period was not required for patient inclusion

Clinical characteristics {#Sec4}
------------------------

The period of follow-up was calculated from the date of AIP recognition to that of most recent follow-up with imaging modalities or the date of PaT diagnosis in cases of concurrent PaT. Biopsy results at the initial visit were noted. The levels of serum IgG4 (normal range, ≤2 g/L) at the time of AIP diagnosis were categorized into within, 1--2 times and \>2 times upper limit of normal value \[[@CR2]\]. The absolute values of serum CA-199 (normal range, 0-35 U/ml) at the time of AIP diagnosis were also documented. Considering that different patients underwent examinations covering different body parts due to different physicians' or patients' preferences, the assessment of extrapancreatic involvement was limited to the typical organs involved in the abdomen, which included the bile ducts, kidneys, and retroperitoneum. In the absence of recent invasive procedures, neoplastic or infectious lesions in assessed organs, the extrapancreatic involvement was considered present on images if the bile ducts demonstrated thickening and contrast enhancement, the kidneys presented with round or wedge-shaped hypoattenuating lesions with moderate enhancement on contrast enhanced images, and the retroperitoneum was confined by a thick soft-tissue mass, respectively (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR5], [@CR15]\]. Fig. 2Typical CT and MR imaging appearance of type 1 autoimmune pancreatitis. Axial pre-enhanced (**a**), arterial (**b**), venous (**c**) phase on CT images and axial T2WI (**e**), T1WI (**f**), pancreatic (**g**), portal venous (**h**) and delayed venous (**i**) phase on MR imaging showed diffuse pancreatic enlargement with homogenous enhancement (star sign). On MR imaging, it appeared hypointense during the pancratic phase (**g**) compared with the spleen, and became hyperintense during the portal venous phase (**h**) compared with the pancreatic phase (**g**) and isointense during the delayed venous phase (**i**) compared with the portal venous phase (**h**). Peripancreatic vessel stricture (straight white arrows) was observed on both CT and MR images (**b**, **c**, **g**, **h** and **i**). Extrapancreatic involvement including the common bile duct (curved white arrows on **g**, **h** and **i**) and kidney (straight black arrows on **d** and **g**) were noted. The MR cholangiopancreatography (**j**) showed the stricture of the common bile duct and the dilatation of the upstream extrahepatic duct (curved white arrow)

CT imaging characteristics {#Sec5}
--------------------------

The pattern of pancreatic enlargement was recorded as either focal or diffuse. The presence or absence of pancreatic heterogeneity and low-density on enhanced images (arterial or venous phase), presence of pancreatic parenchymal atrophy, MPD dilatation (≥5 mm) \[[@CR2]\] and cutoff, peripancreatic halo sign (capsule-like low-density rim), stranding, ascites and vessel stricture was evaluated (Fig. [2](#Fig2){ref-type="fig"}). If there were pre-existed hypodense areas in the pancreatic parenchyma, the shape, relative density and absolute density (Hounsfield, Hu) of low-density region were also recorded. The shape of hypodensity was noted as mass-like or non-mass-like. The relative density was noted as hypoattenuating, isoattenuating or hyperattenuating relative to the normal pancreatic parenchyma on arterial and venous phase images. A region of interest (ROI) was placed around the largest axial low-density region and drawn as large as possible excluding edge pixels to avoid partial volume effect. The mean absolute density values of ROIs (Hu) were separately measured on pre-enhanced, arterial and venous phase images.

MR imaging characteristics {#Sec6}
--------------------------

If patients also underwent MR before invasive procedures, the following MRI characteristics were assessed: 1) the pattern of pancreatic parenchyma involvement (focal or diffuse); 2) pancreatic parenchymal atrophy (present or absent); 3) the signal intensity of pancreatic parenchyma (hypo-, iso-, or hyperintense; homogenous or heterogeneous) compared with the unaffected pancreatic parenchyma or the liver on T1- and T2-weighted images; 4) contrast enhancement of pancreatic parenchyma (hypo-, iso-, or hyperintense; homogenous or heterogeneous) during the pancreatic phase compared with the unaffected pancreatic parenchyma or the spleen; 5) contrast enhancement of pancreatic parenchyma (hypo-, iso-, or hyperintense; homogenous or heterogeneous) during the portal venous phase compared with the pancreatic phase; 6) contrast enhancement of pancreatic parenchyma (hypo-, iso-, or hyperintense; homogenous or heterogeneous) during the delayed venous phase compared with the portal venous phase \[[@CR17]\]; 7) rim enhancement of parenchyma on enhanced sequences (present or absent); 8) MPD dilatation (≥5 mm) \[[@CR2]\] and cutoff (present or absent); 9) peripancreatic halo sign (capsule-like hyperintensity on T2WI and enhancement on delayed venous sequences) \[[@CR18]\], stranding, ascites and vessel stricture (present or absent) (Fig. [2](#Fig2){ref-type="fig"}).

Statistical analysis {#Sec7}
--------------------

Statistical analysis was performed with IBM SPSS Statistics software (version 21.0 J; SPSS, Chicago, IL). The Fisher's exact test was used for qualitative variables, and nonparametric Mann-Whitney test for quantitative variables. A *p* value ≤0.05 was considered statistically significant.

Results {#Sec8}
=======

Characteristics of type 1 AIP patients with PaT {#Sec9}
-----------------------------------------------

Of the included 74 type 1 AIP patients, 5 (6.7%,) were found to have the concurrent PaT. 3 cases (5.4%) were from the first institution and 2 (11.1%) from the second institution. The subtypes of the concurrent PaT were pancreatic ductal adenocarcinoma (PDAC) (3/5), solitary extramedullary plasmacytoma (SEP) in the pancreas (1/5) and cholangiocarcinoma (CC) in the pancreatic segment (1/5). Two patients (PDAC and CC) underwent pancreatic resection, and the remaining 3 cases were confirmed on the biopsy. The sizes of PADC and CC measured in specimen were 43 mm × 35 mm × 30 mm and 20 mm × 15 mm × 10 mm (compared with size of 43 mm × 32 mm × 29 mm and 18 mm × 14 mm × 12 mm measured on CT), respectively. The invasion to peripancreatic vessel was observed in the resected PDAC case, and the invasion to duodenum was noted in CC case. No metastases to lymph nodes were histologically noted in the two resected cases. The clinical and CT imaging characteristics of the 5 AIP patients with PaT were summarized in Table [1](#Tab1){ref-type="table"}. Table 1Summary of Clinical and CT Imaging Characteristics of Type 1 AIP Patients with PaTPDAC (*n* = 3)SEP (*n* = 1)CC^a^\
(n = 1)Case 1^a^Case 2Case 3GenderMaleMaleFemaleFemaleFemaleSurveillance period (month)30036IgG4 (≤2 g/L, g/L)6.95.24.60.34.1CA-199 (0-35 U/ml, U/ml)64.714.6106.02.021.4Biopsy at initial visit LocationPancreasPancreasPancreasPancreasPancreas Evidence of PaTNoYesYesNoNoPresence of extrapancreatic involvement Bile ductNoNoYesYesYes KidneyNoNoNoNoNo RetroperitoneumNoYesNoYesNoCT imaging characteristics of pancreatic parenchyma Focal enlargementYesYesYesYesYes Presence of atrophyNoNoYesNoNo Presence of heterogeneityYesYesYesYesYes Presence of low-densityYesYesYesYesYes  Mass-likeYesYesYesNoYes  Relative density   Arterial phaseHypoHypoHypoHypoHypo   Venous phaseHypoHypoHypoHypoIso  Absolute density (Hu)   Pre-enhanced phase3845284545   Arterial phase5351327689   Venous phase6881379494CT imaging characteristics of main pancreatic duct DilatationYesNoNoNoNo CutoffYesNoYesNoNoCT imaging characteristics of peripancreatic structures Presence of halo signYesNoNoYesNo Presence of strandingYesNoYesYesNo Presence of ascitesNoNoNoYesNo Presence of vessel strictureYesYesYesYesNo*Abbreviations*: *AIP* autoimmune pancreatitis, *PaT* pancreatic tumor, *PDAC* pancreatic ductal adenocarcinoma, *SEP* solitary extramedullary plasmacytoma, *CC* cholangiocarcinoma, *Hypo* hypoattenuating, *Iso* Isoattenuating, *Hu* Hounsfield^a^ Marked cases underwent pancreatic resection, and the presence of concurrent PaT in other unmarked cases were proved by biopsy at the initial visit or in the surveillance period

Two cases of PDAC were suspected due to the presentation of a mass-like hypodensity on the pancreatic head on CT scans, which were confirmed by the endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) of pancreas at the initial visit. They were recognized at the same time of AIP diagnosis, so the surveillance period were noted as 0 month. The presences of SEP, CC and the third PDAC case were suspected due to progression of size identified on follow-up CT. The surveillance periods were 3, 6 and 3 months, respectively. Notably, all three patients underwent EUS-FNA of pancreas initially, for which the results showed no evidence of tumor. The AIP patient with SEP underwent ^18^F-FDG PET/CT after the follow-up abnormal CT. The result of ^18^F-FDG PET/CT indicated the concurrent presence of a different entity from the underlying AIP, where a focal avid FDG uptake in the background of moderate FDG uptake was evident in the pancreas (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Type 1 autoimmune pancreatitis (AIP) with concurrent pancreatic solitary extramedullary plasmacytoma (SEP). Several areas of non-mass-like low-density (white and black arrows) in pancreas were found on arterial phase CT image (**b**). They appeared hypoattenuating on pre-enhanced (**a**) and venous (**c**) phase CT images. It was hard to differentiate SEP (black arrow) from the underlying AIP (white arrow) based on CT imaging findings (**a**, **b** and **c**). Fused fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography/CT (^18^F-FDG PET/CT) (**d**) showed focal avid FDG uptake (black arrow) in the background of moderate FDG uptake (white arrow), which indicated there were two different entities present in the pancreas. The second biopsy of pancreas in the surveillance period showed dense infiltration of plasmacytoid cells on haematoxylin-eosin stain, original magnification × 200 (e-1). The plasmacytoid cells showed positive staining for CD138 (e-2), CD38 (e-3) and monotypic k-light chain (e-4), and negative staining for monotypic λ-light chain(e-5) on immunohistochemical stain, original magnification × 200

Comparison of clinical characteristics {#Sec10}
--------------------------------------

Gender (*p* = 0.044) was a statistically significant factor that differed between AIP patients with and without PaT. 3 of 5 AIP patients with PaT were females. The levels of serum IgG4 and CA-199 were separately measured in 65 patients. There was no significant difference in respect to age, surveillance period, inclusion of biopsy, serum IgG4 or CA-199 levels, or extrapancreatic involvement between the two groups (*p*\>0.05) (Table [2](#Tab2){ref-type="table"}). Table 2Comparison of Clinical and CT imaging Characteristics between Type 1 AIP Patients with and without PaTAIP (*n* = 69)AIP + PaC (*n* = 5)*P* ValueMale58 (84%)2 (40%)0.044Age (year)61 (24--80)58 (42--76)0.845Surveillance period (month)5 (1--109)3 (0--6)0.086IgG4 (*n* = 65)0.561 \<1 time upper limit8 (14%)1 (20%) 1--2 times upper limit11 (17%)0 (0%)  ≥ 2 times upper limit41 (69%)4 (80%)CA-199 (n = 65, U/ml)19.5 (2.0--1987.0)21.4 (2.0--106.0)0.767Biopsy at the initial visit41 (58%)5 (100%)0.150Presence of extrapancreatic involvement Bile duct63 (91%)3 (60%)0.087 Kidney25 (36%)0 (0%)0.160 Retroperitoneum9 (9%)2 (40%)0.157CT imaging characteristics of pancreatic parenchyma Enlargement pattern0.003  Diffuse49 (71%)0 (0%)  Focal20 (29%)5 (100%) Presence of atrophy10 (15%)1 (20%)0.564 Presence of heterogeneity28 (41%)5 (100%)0.015 Presence of low-density (*n* = 26)21 (30%)5 (100%)0.004  Mass-like low-density6 (29%)4 (80%)0.055  Relative density of low-density   Arterial phase1.000    Hypoattenuating21 (100%)5 (100%)    Isoattenuating0 (0%)0 (0%)    Hyperattenuating0 (0%)0 (0%)   Venous phase0.562    Hypoattenuating14 (67%)4 (80%)    Isoattenuating7 (33%)1 (20%)    Hyperattenuating0 (0%)0 (0%)  Absolute density of low-density (Hu)   Pre-enhanced phase42 (33--53)45 (28--45)0.769   Arterial phase71 (51--96)53 (32--89)0.313   Venous phase83 (57--112)81 (37--94)0.255CT imaging characteristics of main pancreatic duct Presence of dilatation16 (23%)1 (20%)1.000 Presence of cutoff31 (45%)2 (40%)1.000CT imaging characteristics of peripancreatic structures Presence of halo sign43 (62%)2 (40%)0.374 Presence of stranding14 (20%)3 (60%)0.076 Presence of ascites2 (3%)1 (20%)0.192 Presence of vessel stricture44 (64%)4 (80%)0.651*Abbreviations*: *AIP* autoimmune pancreatitis, *PaT* pancreatic tumor, *Hu* HounsfieldQuantitative data are expressed as median (range), qualitative data as absolute values (percentages)

Comparison of CT imaging characteristics {#Sec11}
----------------------------------------

The pattern of pancreatic enlargement (*p* = 0.003), the presence of pancreatic heterogeneity (*p* = 0.015) and low-density (*p* = 0.004) were significantly different between AIP patients with and without PaT. All of the 5 AIP patients with concurrent PaT demonstrated the CT imaging features of focal pancreatic enlargement, pancreatic heterogeneity and low-density (Table [2](#Tab2){ref-type="table"}). Of note, there were 3 pure AIP patients (2 of 3 from the first medical institution) who presented with focal pancreatic enlargement, heterogeneity and mass-like low-density on CT in our cohort (Fig. [4](#Fig4){ref-type="fig"}). All of them eventually underwent pancreatic resection due to high suspicion of concurrent PaT. Other CT imaging characteristics of pancreatic parenchyma, MPD or peripancreatic structures did not differ significantly between the two groups (p\>0.05) (Table [2](#Tab2){ref-type="table"}). None of the low-density imaging characteristics on CT could significantly differentiate the two groups (*p*\>0.05) (Table [2](#Tab2){ref-type="table"}). Fig. 4Type 1 autoimmune pancreatitis (AIP) without concurrent pancreatic tumor. Axial pre-enhanced (**a**), arterial (**b**), venous (**c**) phase on CT and axial T2WI (**d**), T1WI (**e**), pancreatic (**f**), portal venous (**g**) and delayed venous (**h**) phase on MR imaging showed a focal lesion in the pancreatic head (straight black arrows). It presented with mass-like low-density on enhanced CT images (**b** and **c**). MR images showed a focal lesion with nearly homogeneous enhancement on enhanced sequences (**f**, **g** and **h**). The presence of focal mass-like lesion, combined with the characteristics of distal pancreatic parenchymal atrophy and main pancreatic ductal dilatation (curved white arrow on **i**), led to the high suspicion of pancreatic tumor. This patient finally underwent pancreatic resection and was proved to be pure AIP histologically. Kidney involvement was also observed on both CT and MR imaging (straight white arrows on **b**, **c**, **d**, **f**, **g** and **h**)

Comparison of MR imaging characteristics {#Sec12}
----------------------------------------

Among the included patients, 20 patients had the available MR imaging data that were analyzed. Only one case (PDAC from the first medical center) was from the AIP + PaT group, which appeared as a focal lesion with rim enhancement (Fig. [5](#Fig5){ref-type="fig"}). None of the pure AIP cases showed the feature of rim enhancement, even in the cases with focal pancreatic enlargement (Fig. [4](#Fig4){ref-type="fig"}). It differed significantly between the comparing groups (*p* = 0.050). None of the other evaluated MR imaging characteristics worked significantly (*p*\>0.05) (Table [3](#Tab3){ref-type="table"}). Fig. 5Type 1 autoimmune pancreatitis with concurrent pancreatic ductal adenocarcinoma. Axial pre-enhanced (**a**), arterial (**b**), venous (**c**) phase on CT and axial T2WI (**d**), T1WI (**e**), pancreatic (**f**), portal venous (**g**) and delayed venous (**h**) phase on MR imaging showed a focal lesion in the pancreatic head (straight black arrows). It appeared as low-density on enhanced CT images (**b** and **c**). The imaging characteristic of rim enhancement was noted on enhanced MR images (**f**, **g** and **h**), which was not obvious on CT. Distal pancreatic parenchymal atrophy was observed (straight white arrows on **a**-**h**). Kidney involvement was also seen (curved white arrows on **b** and **c**) Table 3Comparison of MR imaging Characteristics between Type 1 AIP Patients with and without PaTAIP (*n* = 19)AIP + PaC (n = 1)*P* ValuePancreatic parenchyma Enlargement pattern0.250  Diffuse15 (79%)0 (0%)  Focal4 (21%)1 (100%) Presence of atrophy2 (11%)1 (100%)0.150 Signal intensity on T1WI  Hypointense16 (84%)1 (100%)0.911  Isointense2 (11%)0 (0%)  Hyperintense1 (5%)0 (0%)  Presence of heterogeneity5 (26%)0 (0%)1.000 Signal intensity on T2WI  Hypointense0 (0%)0 (0%)0.452  Isointense7 (37%)0 (0%)  Hyperintense12 (63%)1 (100%)  Presence of heterogeneity6 (31%)1 (100%)0.300 Signal intensity on pancreatic phase  Hypointense13 (69%)1 (100%)0.502  Isointense6 (31%)0 (0%)  Hyperintense0 (0%)0 (0%)  Presence of heterogeneity12 (63%)1 (100%)1.000 Signal intensity on portal venous phase  Hypointense1 (5%)0 (0%)0.798  Isointense5 (26%)0 (100%)  Hyperintense13 (69%)1 (0%)  Presence of heterogeneity6 (31%)1 (100%)0.350 Signal intensity on delayed venous phase  Hypointense3 (16%)0 (0%)0.753  Isointense12 (63%)1 (100%)  Hyperintense4 (21%)0 (0%)  Presence of heterogeneity5 (26%)1 (100%)0.300 Presence of rim enhancement0 (0%)1 (100%)0.050Main pancreatic duct Presence of dilatation3 (16%)0 (0%)1.000 Presence of cutoff6 (31%)1 (100%)0.350Peripancreatic structures Presence of halo sign1 (5%)0 (0%)1.000 Presence of stranding0 (0%)0 (0%)1.000 Presence of ascites0 (0%)0 (0%)1.000 Presence of vessel stricture13 (69%)1 (100%)1.000*Abbreviations*: *AIP* autoimmune pancreatitis, *PaT* pancreatic tumorData are expressed as absolute values (percentages)

Discussion {#Sec13}
==========

In the present study, we found that the gender, pattern of pancreatic enlargement, pancreatic heterogeneity, low-density on enhanced CT and rim enhancement on MRI were significantly different between type 1 AIP patients with and without PaT. 3 of 5 AIP + PaT patients were females. All of them demonstrated focal pancreatic enlargement, heterogeneity and low-density on CT. The details of low-density on CT didn't work significantly. Only one AIP + PcT patient had the MRI data, and showed the characteristic of rim enhancement. None of the pure AIP patients presented with rim enhancement on MR imaging. According to our knowledge, there was only one comparable study that has attempted to identify the difference between type 1 AIP patients with and without PaT, but no statistically significant differences were concluded \[[@CR8]\].

The prevalence of PaT in AIP patients was about 5.4% (3/56) in the first medical institution and 11.1% (2/18) in the second medical institution. The general prevalence of concurrent PaT in type 1 AIP in the two institutions was about 6.7% (5/74), which was higher than other studies \[[@CR5]--[@CR9], [@CR11], [@CR12]\]. The reason for the higher prevalence of PaT in AIP patients, especially in the second medical institution, may be a result of potential selection bias. The second institution is a cancer specific center, where non-cancer patients such as pure AIP cases may not be referred for surveillance. The definite association between AIP and PaT remained inconclusive. Some researchers have suggested that AIP may be a manifestation of paraneoplastic syndrome \[[@CR10], [@CR16]\], some have indicated that chronic pancreatic inflammation in AIP may contribute to carcinogenesis \[[@CR8], [@CR12], [@CR19]\], and some have reported that AIP was not associated with an increased incidence of total malignancies \[[@CR20], [@CR21]\]. Our results tended to support the hypothesis of paraneoplastic syndrome, which would be briefly explained below.

The concurrent PaTs were identified 0, 3 and 6 months after the diagnosis of AIP, respectively. But during retrospective review, all of the PaTs were concurrently present with AIP (this synchronous occurrence may indicate the association between AIP and paraneoplastic syndrome). Several studies have reported that the occurrence of cancer in AIP patients was significantly higher in the first year than in the subsequent years \[[@CR12], [@CR16]\]. Accordingly, some PaTs were identified at the same time of AIP diagnosis and some were found during the follow-up period that could last as long as 186 months \[[@CR7]--[@CR9], [@CR12], [@CR22], [@CR23]\]. Therefore optimal surveillance duration in AIP patients cannot be concluded for early PaT detection. However, close observation should be warranted during the first year post diagnosis of AIP given the diagnostic challenge and relatively high incidence during the first year. In this cohort, the delay in diagnosing the concurrent PaT was mainly attributed to the negative EUS-FNA results of pancreas at the initial visit. It indicated that the negative EUS-FNA results of pancreas couldn't rule out the presence of PaT, which was consistent with the results of some previous studies \[[@CR19], [@CR24]\]. Several studies showed that serum IgG4 levels at the diagnosis of AIP were significantly higher in AIP patients with cancer than those without cancer \[[@CR12], [@CR16]\]. In our study, the serum IgG4 level in 4 of 5 AIP + PaT patients went beyond the 2 times upper limit of normal value, though it didn't differ significantly between AIP patients with and without PaT. The types of included cancers in the previous studies were mainly non-PaT tumors \[[@CR12], [@CR16]\], it remains questionable whether different types of concurrent cancer would result in different levels of serum IgG4 elevation. Age, serum CA-199 levels or extrapancreatic involvements did not vary significantly between the two groups, which were consistent with previous studies \[[@CR8], [@CR12]\]. In the current study, the only significant clinical characteristic was gender and 3 of 5 AIP patients with PaT were females. Comparably, Ikeura et al. found that 2 out of 3 AIP patients with PaT were females, though gender difference between the two groups didn't reach statistical significance \[[@CR8]\]. However, there were previous studies where the reported AIP + PaT patients were all males \[[@CR9], [@CR19]\]. The reason for the discrepancy between our and previous study is unknown. This may be due to the limited sample size in both current and previous studies. The female AIP + PaT predominance in our cohort may suggest that at least some AIP cases are associated with paraneoplastic syndrome. When type 1 AIP appears in an uncommon population, intense attention should be paid to exclude the concurrent presence of a tumor.

The CT imaging characteristics of focal pancreatic enlargement, pancreatic heterogeneity and low-density on enhanced phase were significantly different between AIP patients with and without PaT in this cohort. All of the three CT imaging features were detected in all of the 5 cases with accompanied PaT. Comparably, Ikeura et al. also found that all of the 3 AIP patients who developed PaT showed the feature of focal pancreatic enlargement, but this characteristic didn't differ significantly between the comparison groups \[[@CR8]\]. When the inclusion criteria was set as focal pancreatic enlargement that underwent resection, the incidence of concurrent PaT in type 1 AIP could be as high as 33.3% (2/6) \[[@CR19]\], which was much higher than previously mentioned. Besides, Ikeura et al. found 2 out of 3 AIP + PaT patients presented with pancreatic low-density, but statistical significance was not provided \[[@CR8]\]. The international consensus considers pancreatic low-density as an atypical imaging finding of AIP and suggests such patients should be managed as PaT unless an alternative diagnosis is strongly suspected \[[@CR2]\]. Therefore concurrent pancreatic malignancy needs to be excluded in the presence of focal pancreatic enlargement and low-density in AIP. Notably, focal pancreatic enlargement, pancreatic heterogeneity and low-density did appear in pure AIP cases as we have shown, so the presence of these features do not validate concurrent PaT. Furthermore, the diagnosis cannot be further made easier by the interpretation of other CT imaging characteristics. 4 of 5 AIP patients with accompanied PaT presented with mass-like low-density despite no statistically significant difference was observed between AIP patients with and without PaT. Notably, the shape of mass-like low-density was also noted in small portions of pure AIP cases (6/21). Our results showed that the sizes of concurrent PaT measured in specimen were comparable with initial CT measurement, which indicated the presence of mass-like low-density was highly suggestive of concurrent tumor. However, when the tumor was too small to exceed the contour of pancreas on imaging, it was hard to conclude the presence of concurrent PaT. In this situation, close surveillance was of vital importance, which was supported by the fact that 3 cases of AIP + PaT became highly suspicious for malignancy during the follow-up period in our cohort. On the other hand, if the PaT was very large and appeared obvious in the background of pancreas on imaging, the diagnosis of AIP + PaT may be easy to make. Consequently, the morphologic criteria should be modified with the stage or the size of the tumor. The effect of size difference between pathology and radiology on the interpretation of mass-like low-density needs future investigations to explore, where larger sample size are warranted. In this cohort, the low-density areas in both AIP and PaT portions presented as hypoattenuating region during arterial phase and either hypoattenuating or isoattenuating during venous phase. There was not statistically significant absolute density value identified to indicate the underlying pathological differences between the two. So the presence of pancreatic low-density regions on CT in patients with AIP was only suggestive for the presence of concurrent PaT. Other imaging characteristics suggestive of PaT include MPD dilatation, pancreatic parenchymal atrophy and peripancreatic vessel stricture. However, these characteristics were also noted in pure AIP cases, which was in accordance with previous studies \[[@CR3], [@CR14], [@CR25]\]. These imaging features in AIP may be attributed to the longstanding intra- and peri-pancreatic inflammation and fibrosis in AIP.

In the aspect of MR imaging characteristics, our results showed that AIP + PaT patient could present with rim enhancement on MR imaging, and none of the included pure AIP cases showed this imaging characteristic. So it may be a useful MR imaging characteristic to differentiate pure AIP cases from AIP + PaT cases. However, neither the role of MR imaging characteristics in differentiating AIP patients with and without PaT nor the presence of rim enchantment on MR imaging in pure AIP cases has ever been studied previously \[[@CR17], [@CR18]\]. Moreover, there was only one AIP + PaT case included in the present cohort. So it is still too early to draw a final conclusion on the role of MR imaging in differentiating the two groups, and future studies with larger sample size are recommended.

Besides CT and MR, the case of AIP with SEP in our study implies that ^18^F-FDG PET/CT may add some value where the difference in FDG uptake may help identify the concurrent PaT. However, Shiokawa et al. \[[@CR16]\] reported that none of AIP patients with cancer were identified with ^18^F-FDG PET/CT, though there was no case of PaT in their cohort. Further studies are required before definitive conclusion can be made.

There are limitations to our study. Firstly, though we have included the AIP + PaT data of two institutions, only a small size of cases was identified due to its rare entity. Secondly, the AIP patients in the two medical institutions follwed different diagnostic and follow-up pathways due to various reasons where different imaging modalities were used for surveillance which further limited the sample size as some did not meet the selection criteria.

Conclusion {#Sec14}
==========

When type 1 AIP patients are females and present with focal pancreatic enlargement, pancreatic heterogeneity, low-density on CT and rim enhancement on MR imaging, it should be prudent to exclude the synchronous presence of PaT. The CT imaging characteristics of pancreatic low-density or other MR imaging characteristics of intra−/peri-pancreatic structures are not reliable to conclude the presence of concurrent PaT.
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:   fluorine 18 fluorodeoxyglucose positron emission tomography/CT

AIP

:   Autoimmune pancreatitis

CC

:   Cholangiocarcinoma

EUS-FNA

:   Endoscopic ultrasonography-guided fine needle aspiration

MPD

:   Main pancreatic duct

PaT

:   Pancreatic tumor

PDAC

:   Pancreatic ductal adenocarcinoma

SEP

:   Solitary extramedullary plasmacytoma

US

:   Ultrasonography
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